Role of ceftiofur in selection and dissemination of blaCMY-2-mediated cephalosporin resistance in Salmonella enterica and commensal Escherichia coli isolates from cattle.
Third-generation cephalosporin resistance of Salmonella and commensal Escherichia coli isolates from cattle in the United States is predominantly conferred by the cephamycinase CMY-2, which inactivates beta-lactam antimicrobial drugs used to treat a wide variety of infections, including pediatric salmonellosis. The emergence and dissemination of bla(CMY-2)(-)-bearing plasmids followed and may in part be the result of selection pressure imposed by the widespread utilization of ceftiofur, a third-generation veterinary cephalosporin. This study assessed the potential effects of ceftiofur on bla(CMY-2) transfer and dissemination by (i) an in vivo experimental study in which calves were inoculated with competent bla(CMY-2)-bearing plasmid donors and susceptible recipients and then subjected to ceftiofur selection and (ii) an observational study to determine whether ceftiofur use in dairy herds is associated with the occurrence and frequency of cephalosporin resistance in Salmonella and commensal E. coli. The first study revealed bla(CMY-2) plasmid transfer in both ceftiofur-treated and untreated calves but detected no enhancement of plasmid transfer associated with ceftiofur treatment. The second study detected no association (P = 0.22) between ceftiofur use and either the occurrence of ceftiofur-resistant salmonellosis or the frequency of cephalosporin resistance in commensal E. coli. However, herds with a history of salmonellosis (including both ceftiofur-resistant and ceftiofur-susceptible Salmonella isolates) used more ceftiofur than herds with no history of salmonellosis (P = 0.03) These findings fail to support a major role for ceftiofur use in the maintenance and dissemination of bla(CMY-2)-bearing plasmid mediated cephalosporin resistance in commensal E. coli and in pathogenic Salmonella in these dairy cattle populations.
Department of Veterinary Microbiology and Pathology, Washington State University College of Veterinary Medicine, Pullman, WA 99164, USA.
Joshua B
JB
Daniels
Douglas R
DR
Call
Dale
D
Hancock
William M
WM
Sischo
Katherine
K
Baker
Thomas E
TE
Besser
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D002417:Cattle / Q000382:microbiology*; D018550:Cephalosporin Resistance; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D003227:Conjugation, Genetic; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D022761:Gene Transfer, Horizontal; D010957:Plasmids; D019779:Salmonella enterica / Q000187:drug effects* / Q000302:isolation & purification; D012641:Selection, Genetic; D014481:United States; D001618:beta-Lactamases / Q000096:biosynthesis / Q000235:genetics*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C053503:ceftiofur; C103022:beta-lactamase CMY-2; D001618:beta-Lactamases